Wang X, Wang L, Lin H, Zhu Y, Huang D, Lai M, Xi X, Huang J, Zhang W, Zhong T. Research progress of CTC, ctDNA, and EVs in cancer liquid biopsy. Front Oncol. 2024;14:1303335. https://doi.org/10.3389/fonc.2024.1303335.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Z, Li C, Zhou Y, Yao Y, Liu J, Wu M, Su J. Liquid biopsies for cancer: from bench to clinic. MedComm (2020). 2023;4(4):e329. https://doi.org/10.1002/mco2.329

Nikanjam M, Kato S, Kurzrock R. Liquid biopsy: current technology and clinical applications. J Hematol Oncol. 2022;15(1):131. https://doi.org/10.1186/s13045-022-01351-y.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lone SN, Nisar S, Masoodi T, Singh M, Rizwan A, Hashem S, El-Rifai W, Bedognetti D, Batra SK, Haris M, Bhat AA, Macha MA Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments. Mol Cancer. 2022;21(1):79. . https://doi.org/10.1186/s12943-022-01543-7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mishra M, Ahmed R, Das DK, Pramanik DD, Dash SK, Pramanik A Recent advancements in the application of circulating tumor dna as biomarkers for early detection of cancers. ACS Biomater Sci Eng. 2024;10(8):4740–56. https://doi.org/10.1021/acsbiomaterials.4c00606.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Deng Z, Wu S, Wang Y, Shi D. Circulating tumor cell isolation for cancer diagnosis and prognosis. EBioMedicine. 2022;83:104237. https://doi.org/10.1016/j.ebiom.2022.104237.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Honoré N, Galot R, van Marcke C, Limaye N, Machiels JP. Liquid biopsy to detect minimal residual disease: methodology and impact. Cancers (Basel). 2021;13(21):5364. https://doi.org/10.3390/cancers13215364.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cescon DW, Bratman SV, Chan SM, Siu LL. Circulating tumor DNA and liquid biopsy in oncology. Nat Cancer. 2020;1(3):276–90. https://doi.org/10.1038/s43018-020-0043-5.

Article  CAS  PubMed  Google Scholar 

Kresse SH, Brandt-Winge S, Pharo H, Flatin BTB, Jeanmougin M, Vedeld HM, Lind GE. Evaluation of commercial kits for isolation and bisulfite conversion of circulating cell-free tumor DNA from blood. Clin Epigenetics. 2023;15(1):151. https://doi.org/10.1186/s13148-023-01563-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Parums DV A Review of circulating tumor DNA (ctDNA) and the liquid biopsy in cancer diagnosis, screening, and monitoring treatment response. Med Sci Monit. 2025;31:e949300. https://doi.org/10.12659/MSM.949300.

Article  PubMed  PubMed Central  Google Scholar 

Mayerhoefer ME, Kienzle A, Woo S, Vargas HA Update on liquid biopsy. Radiology. 2025;315(3):e241030. https://doi.org/10.1148/radiol.241030.

Article  PubMed  PubMed Central  Google Scholar 

Pessoa LS, Heringer M, Ferrer VP. ctDNA as a cancer biomarker: a broad overview. Crit Rev Oncol Hematol. 2020;155:103109. https://doi.org/10.1016/j.critrevonc.2020.103109.

Article  PubMed  Google Scholar 

Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018;15(9):577-586. https://doi.org/10.1038/s41571-018-0058-3.

Helzer KT, Sharifi MN, Sperger JM, Shi Y, Annala M, Bootsma ML, et al. Fragmentomic analysis of circulating tumor DNA-targeted cancer panels. Ann Oncol. 2023;34(9):813-825. https://doi.org/10.1016/j.annonc.2023.06.001.

Lin D, Shen L, Luo M, Zhang K, Li J, Yang Q, et al. Circulating tumor cells: biology and clinical significance. Signal Transduct Target Ther. 2021;6(1):404. https://doi.org/10.1038/s41392-021-00817-8.

Zhang YW, Gvozdenovic A, Aceto N. A Molecular voyage: multiomics insights into circulating tumor cells. Cancer Discov. 2024;14(6):920-933. https://doi.org/10.1158/2159-8290.CD-24-0218.

Pouyiourou M, Bochtler T, Coith C, Wikman H, Kraft B, Hielscher T, et al. Frequency and prognostic value of circulating tumor cells in cancer of unknown primary. Clin Chem. 2024;70(1):297-306. https://doi.org/10.1093/clinchem/hvad180.

Yu D, Li Y, Wang M, Gu J, Xu W, Cai H,et al. Exosomes as a new frontier of cancer liquid biopsy. Mol Cancer. 2022 Feb 18;21(1):56. https://doi.org/10.1186/s12943-022-01509-9.

Elzanowska J, Semira C, Costa-Silva B. DNA in extracellular vesicles: biological and clinical aspects. Mol Oncol. 2021;15(6):1701-1714. https://doi.org/10.1002/1878-0261.12777.

Garcia-Martin R, Wang G, Brandão BB, Zanotto TM, Shah S, Kumar Patel S, et al. MicroRNA sequence codes for small extracellular vesicle release and cellular retention. Nature. 2022;601(7893):446-451. https://doi.org/10.1038/s41586-021-04234-3.

Gai W, Sun K. Epigenetic biomarkers in cell-free DNA and applications in liquid biopsy. Genes (Basel). 2019;10(1):32. https://doi.org/10.3390/genes10010032.

Kotoh Y, Suehiro Y, Saeki I, Hoshida T, Maeda M, Iwamoto T, et al. Novel Liquid Biopsy Test Based on a Sensitive Methylated SEPT9 Assay for Diagnosing Hepatocellular Carcinoma. Hepatol Commun. 2020;4(3):461-470. https://doi.org/10.1002/hep4.1469.

Botezatu IV, Kondratova VN, Stroganova AM, Dranko SL, Lichtenstein AV. Aberrant methylation scanning by quantitative DNA melting analysis with hybridization probes as exemplified by liquid biopsy of SEPT9 and HIST1H4F in colorectal cancer. Clin Chim Acta. 2023;551:117591. https://doi.org/10.1016/j.cca.2023.117591.

Gu P, Wang Y, Shi C, Chen Y, Qian J, Niu Y, et al. Enhancing the precision of auxiliary diagnosis for lung cancer through use of SHOX2 and RASSF1A methylation status in lung biopsy and lymph node biopsy specimens. Transl Lung Cancer Res. 2025;14(3):897-911. https://doi.org/10.21037/tlcr-2024-1082.

Grossi I, Assoni C, Lorini L, Smussi D, Gurizzan C, Grisanti S, et al. Evaluation of DNA methylation levels of SEPT9 and SHOX2 in plasma of patients with head and neck squamous cell carcinoma using droplet digital PCR. Oncol Rep. 2024;51(3):52. https://doi.org/10.3892/or.2024.8711.

Ding SC, Lo YMD. Cell-free DNa fragmentomics in liquid biopsy. Diagnostics (Basel). 2022;12(4):978. https://doi.org/10.3390/diagnostics12040978.

Ding Z, Wang N, Ji N, Chen ZS. Proteomics technologies for cancer liquid biopsies. Mol Cancer. 2022;21(1):53. https://doi.org/10.1186/s12943-022-01526-8.

Neal RD, Johnson P, Clarke CA, Hamilton SA, Zhang N, Kumar H, et al. Cell-free DNA-based multi-cancer early detection test in an asymptomatic screening population (NHS-Galleri): design of a pragmatic, prospective randomised controlled trial. Cancers (Basel). 2022;14(19):4818. https://doi.org/10.3390/cancers14194818.

Cohen JD, Li L, Wang Y, Thoburn C, Afsari B, Danilova L, et al. Detection and localization of surgically resectable cancers with a multi-analyte blood test. Science. 2018;359(6378):926-930. https://doi.org/10.1126/science.aar3247.

Leja M, Linē A. Early detection of gastric cancer beyond endoscopy - new methods. Best Pract Res Clin Gastroenterol. 2021;50-51:101731. https://doi.org/10.1016/j.bpg.2021.101731.

Raza A, Khan AQ, Inchakalody VP, Mestiri S, Yoosuf ZSKM, Bedhiafi T, et al. Dynamic liquid biopsy components as predictive and prognostic biomarkers in colorectal cancer. J Exp Clin Cancer Res. 2022 Mar 15;41(1):99. https://doi.org/10.1186/s13046-022-02318-0.

Zhou H, Zhu L, Song J, Wang G, Li P, Li W, et al. Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer. Mol Cancer. 2022 Mar 25;21(1):86. https://doi.org/10.1186/s12943-022-01556-2

Casagrande GMS, Silva MO, Reis RM, Leal LF. Liquid biopsy for lung cancer: up-to-date and perspectives for screening programs. Int J Mol Sci. 2023;24(3):2505. https://doi.org/10.3390/ijms24032505.

Bararia A, Chakraborty P, Roy P, Chattopadhay BK, Das A, Chatterjee A, Sikdar N. Emerging role of non-invasive and liquid biopsy biomarkers in pancreatic cancer. World J Gastroenterol. 2023;29(15):2241-2260. https://doi.org/10.3748/wjg.v29.i15.2241.

Guo W, Ying P, Ma R, Jing Z, Ma G, Long J, et al. Liquid biopsy analysis of lipometabolic exosomes in pancreatic cancer. Cytokine Growth Factor Rev. 2023;73:69-77. https://doi.org/10.1016/j.cytogfr.2023.07.006.

Farshchi F, Hasanzadeh M Microfluidic biosensing of circulating tumor cells (CTCs): Recent progress and challenges in efficient diagnosis of cancer. Biomed Pharmacother. 2021;134:111153. . https://doi.org/10.1016/j.biopha.2020.111153.

Article  CAS  PubMed  Google Scholar 

Hu Y, Ulrich BC, Supplee J, Kuang Y, Lizotte PH, Feeney NB, et al False-positive plasma genotyping due to clonal hematopoiesis. Clin Cancer Res. 2018;24(18):4437–43. https://doi.org/10.1158/1078-0432.CCR-18-0143.

Article  CAS  PubMed  Google Scholar 

Vellanki PJ, Ghosh S, Pathak A, Fusco MJ, Bloomquist EW, Tang S, et al. Regulatory implications of ctDNA in immuno-oncology for solid tumors. J Immunother Cancer. 2023;11(2):e005344. https://doi.org/10.1136/jitc-2022-005344.

Mohanty A, Mohanty SK, Rout S, Pani C. Liquid Biopsy, the hype vs. hope in molecular and clinical oncology. Semin Oncol. 2021;48(3):259-267. https://doi.org/10.1053/j.seminoncol.2021.06.002.

Parikh AR, Mojtahed A, Schneider JL, Kanter K, Van Seventer EE, Fetter IJ, et al. Serial ctDNA Monitoring to Predict Response to Systemic Therapy in Metastatic Gastrointestinal Cancers. Clin Cancer Res. 2020;26(8):1877-1885. https://doi.org/10.1158/1078/0432.CCR-19-3467.

Cheng H, Liu C, Jiang J, Luo G, Lu Y, Jin K, et al. Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients. Int J Cancer. 2017; 140(10):2344-2350. https://doi.org/10.1002/ijc.30650.

Dal Maso A, Del Bianco P, Cortiula F, Nardo G, Zulato E, Bonanno L, et al. EGFR T790M testing through repeated liquid biopsy over time: a real-world multicentric retrospective experience. J Thorac Dis. 2022;14(9):3364-3375. https://doi.org/10.21037/jtd-22-745.

Güttlein L, Luca MR, Esteso F, Fresno C, Mariani J, Otero Pizarro M, et al. Liquid biopsy for KRAS, NRAS and BRAF mutation testing in advanced colorectal cancer patients: the Argentinean experience. Future Oncol. 2022;18(29):3277-3287. https://doi.org/10.2217/fon-2022-0329.

Hanna GJ, Dennis MJ, Scarfo N, Mullin MS, Sethi RKV, Sehgal K, et al. Personalized ctDNA for monitoring disease status in head and neck squamous cell carcinoma. Clin Cancer Res. 2024;30(15):3329-3336. https://doi.org/10.1158/1078-0432.CCR-24-0590.

Nakamura Y, Tsukada Y, Matsuhashi N, Murano T, Shiozawa M, Takahashi Y, et al. Colorectal cancer recurrence prediction using a tissue-free epigenomic minimal residual disease assay. Clin Cancer Res. 2024;30(19):4377-4387. https://doi.org/10.1158/1078-0432.CCR-24-1651.

Koukourakis IM, Xanthopoulou E, Koukourakis MI. Using liquid biopsy to predict relapse after radiotherapy in squamous cell head-neck and esophageal Cancer. Cancer Diagn Progn. 2023;3(4):403-410. https://doi.org/10.21873/cdp.10232.

Pantel K, Alix-Panabières C. Liquid biopsy and minimal residual disease - latest advances and implications for cure. Nat Rev Clin Oncol. 2019;16(7):409-424. https://doi.org/10.1038/s41571-019-0187-3.

Dao J, Conway PJ, Subramani B, Meyyappan D, Russell S, Mahadevan D. Using cfDNA and ctDNA as oncologic markers: a path to clinical validation. Int J Mol Sci. 2023;24(17):13219. https://doi.org/10.3390/ijms241713219.

Bauml JM, Li BT, Velcheti V, Govindan R, Curioni-Fontecedro A, Dooms C, et al. Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib. Lung Cancer. 2022;166:270-278. https://doi.org/10.1016/j.lungcan.2021.10.007.

Woodhouse R, Li M, Hughes J, Delfosse D, Skoletsky J, Ma P, et al. Clinical and analytical validation of FoundationOne liquid CDx, a novel 324-Gene cfDNA-based comprehensive genomic profiling assay for cancers of solid tumor origin. PLoS ONE. 2020;15(9):e0237802. https://doi.org/10.1371/journal.pone.0237802.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lin KW. mSEPT9 (Epi proColon) Blood test for colorectal cancer screening. Am Fam Physician. 2019;100(1):10–11.

Abbosh C, Frankell AM, Harrison T, Kisistok J, Garnett A, Johnson L, et al Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616(7957):553–62. https://doi.org/10.1038/s41586-023-05776-4.

Tie J, Wang Y, Lo SN, Lahouel K, Cohen JD, Wong R,et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer: 5-year outcomes of the randomized DYNAMIC trial. Nat Med. 2025;31(5):1509-1518. https://doi.org/10.1038/s41591-025-03579-w.

Batool SM, Yekula A, Khanna P, Hsia T, Gamblin AS, Ekanayake E, et al. The liquid biopsy consortium: challenges and opportunities for early cancer detection and monitoring. Cell Rep Med. 2023;4(10):101198. https://doi.org/10.1016/j.xcrm.2023.101198.

Hallermayr A, Benet-Pagès A, Steinke-Lange V, Mansmann U, Rentsch M, Holinski-Feder E, et al. Liquid biopsy hotspot variant assays: analytical validation for application in residual disease detection and treatment monitoring. Clin Chem. 2021 Nov 1;67(11):1483-1491. https://doi.org/10.1093/clinchem/hvab124.

Coppola CA, De Summa S, Matera G, Pilato B, Traversa D, Tommasi S. Liquid biopsy: the challenges of a revolutionary approach in oncology. Int J Mol Sci. 2025;26(11):5013. https://doi.org/10.3390/ijms26115013

Spoor J, Eyck BM, Atmodimedjo PN, Jansen MPHM, Helmijr JCA, Martens JWM, et al Liquid biopsy in esophageal cancer: a case report of false-positive circulating tumor DNA detection due to clonal hematopoiesis. Ann Transl Med. 2021;9(15):1264. https://doi.org/10.21037/atm-21-525.

Aziz Z, Wagner S, Agyekum A, Pumpalova YS, Prest M, Lim F, Rustgi S, Kastrinos F, Grady WM, Hur C. Cost-effectiveness of liquid biopsy for colorectal cancer screening in patients who are unscreened. JAMA Netw Open. 2023;6(11):e2343392. https://doi.org/10.1001/jamanetworkopen.2023.43392.

Zhang X, Li B. Updates of liquid biopsy in oral cancer and multiomics analysis. Oral Dis. 2023;29(1):51-61. https://doi.org/10.1111/odi.14064.

Ginghina O, Hudita A, Zamfir M, Spanu A, Mardare M, Bondoc I, et al. Liquid biopsy and artificial intelligence as tools to detect signatures of colorectal malignancies: a modern approach in patient's stratification. Front Oncol. 2022;12:856575. https://doi.org/10.3389/fonc.2022.856575.

Ladabaum U, Mannalithara A, Weng Y, Schoen RE, Dominitz JA, Desai M, et al. Comparative effectiveness and cost-effectiveness of colorectal cancer screening with blood-based biomarkers (liquid biopsy) vs fecal tests or colonoscopy. Gastroenterology. 2024;167(2):378-391. https://doi.org/10.1053/j.gastro.2024.03.011.